PT2964646T - Novos derivados de pirazol - Google Patents

Novos derivados de pirazol

Info

Publication number: PT2964646T
Authority: PT; Portugal
Prior art keywords: pyrazol derivatives; novel; novel pyrazol; derivatives; pyrazol
Prior art date: 2013-03-07

Application number

PT147095905T

Other languages

English (en)

Inventor

Grether Uwe

Kimbara Atsushi

Nettekoven Matthias

Ricklin Fabienne

Roever Stephan

Rogers-Evans Mark

Schulz-Gasch Tanja

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-07

Filing date

2014-03-04

Publication date

2017-06-29

2014-03-04 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2017-06-29 Publication of PT2964646T publication Critical patent/PT2964646T/pt

Links

WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Hematology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Psychology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)

PT147095905T 2013-03-07 2014-03-04 Novos derivados de pirazol PT2964646T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP13158233		2013-03-07

Publications (1)

Publication Number	Publication Date
PT2964646T true PT2964646T (pt)	2017-06-29

Family

ID=47827068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT147095905T PT2964646T (pt)	2013-03-07	2014-03-04	Novos derivados de pirazol

Country Status (34)

Country	Link
US (2)	US9512132B2 (pt)
EP (1)	EP2964646B1 (pt)
JP (2)	JP6514119B2 (pt)
KR (2)	KR102217297B1 (pt)
CN (1)	CN105143220B (pt)
AR (1)	AR094978A1 (pt)
AU (1)	AU2014224784B2 (pt)
BR (1)	BR112015020795B1 (pt)
CA (1)	CA2897513C (pt)
CL (1)	CL2015002387A1 (pt)
CR (1)	CR20150447A (pt)
CY (1)	CY1118950T1 (pt)
DK (1)	DK2964646T3 (pt)
EA (1)	EA027935B1 (pt)
ES (1)	ES2629751T3 (pt)
HR (1)	HRP20170919T1 (pt)
HU (1)	HUE034831T2 (pt)
IL (1)	IL240327B (pt)
LT (1)	LT2964646T (pt)
MA (1)	MA38403A1 (pt)
MX (1)	MX363727B (pt)
MY (1)	MY176797A (pt)
NZ (1)	NZ710052A (pt)
PE (1)	PE20151539A1 (pt)
PH (1)	PH12015501843A1 (pt)
PL (1)	PL2964646T3 (pt)
PT (1)	PT2964646T (pt)
RS (1)	RS56148B1 (pt)
SG (1)	SG11201507168XA (pt)
SI (1)	SI2964646T1 (pt)
TW (1)	TWI609866B (pt)
UA (1)	UA118666C2 (pt)
WO (1)	WO2014135507A1 (pt)
ZA (1)	ZA201505073B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA118666C2 (uk) *	2013-03-07	2019-02-25	Ф. Хоффманн-Ля Рош Аг	Похідні піразолу
SI2978755T1 (en)	2013-03-26	2018-03-30	F. Hoffmann-La Roche Ag	New pyridine derivatives
KR20160002857A (ko)	2013-05-02	2016-01-08	에프. 호프만-라 로슈 아게	CB2 수용체 작용제로서의 피롤로[2,3-d]피리미딘 유도체
HUE039589T2 (hu)	2013-05-02	2019-01-28	Hoffmann La Roche	Purinszármazékok mint CB2 receptor agonisták
EP3943497A1 (en)	2013-09-06	2022-01-26	F. Hoffmann-La Roche AG	Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists
US9682985B2 (en) *	2015-03-13	2017-06-20	Abbvie Inc.	(Indazol-4-yl) hexahydropyrrolopyrrolones and methods of use
WO2016191935A1 (en) *	2015-05-29	2016-12-08	Merck Sharp & Dohme Corp.	6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) *	2015-06-04	2016-12-08	Merck Sharp & Dohme Corp.	Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3475281A1 (en)	2016-06-23	2019-05-01	H. Hoffnabb-La Roche Ag	Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
EP3475280B1 (en)	2016-06-23	2020-04-08	H. Hoffnabb-La Roche Ag	Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
EP3475283B1 (en)	2016-06-23	2021-08-11	F. Hoffmann-La Roche AG	Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
KR20230062680A (ko)	2016-06-23	2023-05-09	에프. 호프만-라 로슈 아게	2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체
JP7331921B2 (ja)	2019-03-25	2023-08-23	株式会社ニコン	細胞操作システム及び細胞操作方法
CA3192236A1 (en)	2020-09-10	2022-03-17	Tony Lahoutte	Antibody fragment against fap
WO2023203135A1 (en)	2022-04-22	2023-10-26	Precirix N.V.	Improved radiolabelled antibody
AU2023264245A1 (en)	2022-05-02	2024-12-19	Precirix N.V.	Pre-targeting
CN115246832B (zh) *	2022-06-15	2024-05-24	深圳湾实验室	一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2980677A (en) *		1961-04-18		Certificate of correction
AU2001234958A1 (en) *	2000-02-11	2001-08-20	Bristol-Myers Squibb Company	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CA2479744A1 (en)	2002-03-28	2003-10-09	Paul E. Finke	Substituted 2,3-diphenyl pyridines
DE10219435A1 (de) *	2002-05-02	2003-11-13	Bayer Cropscience Ag	Substituierte Pyrazolo-pyrimidin-4-one
AR051596A1 (es) *	2004-10-26	2007-01-24	Irm Llc	Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2009051705A1 (en)	2007-10-18	2009-04-23	Merck & Co., Inc.	Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
WO2010118367A2 (en) *	2009-04-10	2010-10-14	Progenics Pharmaceuticals, Inc.	Antiviral pyrimidines
US9321727B2 (en)	2011-06-10	2016-04-26	Hoffmann-La Roche Inc.	Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk)	2011-11-08	2016-05-25	Ф. Хоффманн-Ля Рош Аг	ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
JP2015521652A (ja)	2012-07-04	2015-07-30	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	カンナビノイド受容体２アゴニストとしての新規アダマンチル誘導体
JP6426619B2 (ja)	2012-12-07	2018-11-21	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｃｂ２アゴニストとして有用なピリジン−２−アミド
EP3357918A1 (en)	2012-12-07	2018-08-08	F. Hoffmann-La Roche AG	Novel pyridine derivatives
HRP20171459T1 (hr)	2012-12-07	2017-11-03	F. Hoffmann - La Roche Ag	Piridin-2-amidi korisni kao agonisti cb2
PL2928882T3 (pl)	2012-12-07	2017-07-31	F.Hoffmann-La Roche Ag	Pochodne pirazyny jako agoniści receptora cb2
UA118666C2 (uk) *	2013-03-07	2019-02-25	Ф. Хоффманн-Ля Рош Аг	Похідні піразолу

2014
- 2014-03-04 UA UAA201509653A patent/UA118666C2/uk unknown
- 2014-03-04 ES ES14709590.5T patent/ES2629751T3/es active Active
- 2014-03-04 KR KR1020157024230A patent/KR102217297B1/ko active Active
- 2014-03-04 LT LTEP14709590.5T patent/LT2964646T/lt unknown
- 2014-03-04 KR KR1020217003979A patent/KR102369407B1/ko active Active
- 2014-03-04 SI SI201430259T patent/SI2964646T1/sl unknown
- 2014-03-04 BR BR112015020795-2A patent/BR112015020795B1/pt active IP Right Grant
- 2014-03-04 PE PE2015001840A patent/PE20151539A1/es active IP Right Grant
- 2014-03-04 DK DK14709590.5T patent/DK2964646T3/en active
- 2014-03-04 CN CN201480012444.5A patent/CN105143220B/zh active Active
- 2014-03-04 CA CA2897513A patent/CA2897513C/en active Active
- 2014-03-04 MA MA38403A patent/MA38403A1/fr unknown
- 2014-03-04 JP JP2015560654A patent/JP6514119B2/ja active Active
- 2014-03-04 NZ NZ710052A patent/NZ710052A/en not_active IP Right Cessation
- 2014-03-04 MX MX2015011534A patent/MX363727B/es active IP Right Grant
- 2014-03-04 RS RS20170653A patent/RS56148B1/sr unknown
- 2014-03-04 EP EP14709590.5A patent/EP2964646B1/en active Active
- 2014-03-04 HU HUE14709590A patent/HUE034831T2/en unknown
- 2014-03-04 EA EA201591624A patent/EA027935B1/ru not_active IP Right Cessation
- 2014-03-04 MY MYPI2015702926A patent/MY176797A/en unknown
- 2014-03-04 PL PL14709590T patent/PL2964646T3/pl unknown
- 2014-03-04 AU AU2014224784A patent/AU2014224784B2/en active Active
- 2014-03-04 PT PT147095905T patent/PT2964646T/pt unknown
- 2014-03-04 SG SG11201507168XA patent/SG11201507168XA/en unknown
- 2014-03-04 WO PCT/EP2014/054107 patent/WO2014135507A1/en not_active Ceased
- 2014-03-04 HR HRP20170919TT patent/HRP20170919T1/hr unknown
- 2014-03-05 AR ARP140100693A patent/AR094978A1/es active IP Right Grant
- 2014-03-06 TW TW103107745A patent/TWI609866B/zh active
2015
- 2015-07-15 ZA ZA2015/05073A patent/ZA201505073B/en unknown
- 2015-08-03 IL IL240327A patent/IL240327B/en active IP Right Grant
- 2015-08-20 PH PH12015501843A patent/PH12015501843A1/en unknown
- 2015-08-26 CL CL2015002387A patent/CL2015002387A1/es unknown
- 2015-08-27 CR CR20150447A patent/CR20150447A/es unknown
- 2015-09-03 US US14/844,991 patent/US9512132B2/en active Active
2016
- 2016-10-24 US US15/332,398 patent/US9694012B2/en active Active
2017
- 2017-06-16 CY CY20171100638T patent/CY1118950T1/el unknown
2018
- 2018-12-06 JP JP2018229203A patent/JP2019055986A/ja active Pending

Also Published As

Publication number	Publication date
DK2964646T3 (en)	2017-07-10
HRP20170919T1 (hr)	2017-09-22
KR102369407B1 (ko)	2022-03-02
CY1118950T1 (el)	2018-01-10
IL240327B (en)	2019-01-31
KR20150126355A (ko)	2015-11-11
HK1213258A1 (zh)	2016-06-30
EA201591624A1 (ru)	2016-01-29
ES2629751T3 (es)	2017-08-14
HUE034831T2 (en)	2018-03-28
EP2964646A1 (en)	2016-01-13
JP2019055986A (ja)	2019-04-11
JP2016510054A (ja)	2016-04-04
BR112015020795A2 (pt)	2017-07-18
PH12015501843B1 (en)	2015-12-07
MX363727B (es)	2019-04-01
US20150376192A1 (en)	2015-12-31
US20170035769A1 (en)	2017-02-09
MX2015011534A (es)	2016-02-05
CN105143220B (zh)	2018-06-22
CR20150447A (es)	2015-10-08
CL2015002387A1 (es)	2016-03-04
CA2897513C (en)	2021-03-16
SI2964646T1 (sl)	2017-08-31
AU2014224784A1 (en)	2015-07-23
AU2014224784B2 (en)	2018-03-08
SG11201507168XA (en)	2015-10-29
LT2964646T (lt)	2017-07-10
EP2964646B1 (en)	2017-04-19
TWI609866B (zh)	2018-01-01
MA38403A1 (fr)	2017-11-30
IL240327A0 (en)	2015-09-24
TW201506023A (zh)	2015-02-16
MY176797A (en)	2020-08-21
KR20210019578A (ko)	2021-02-22
NZ710052A (en)	2020-09-25
BR112015020795B1 (pt)	2022-08-16
PH12015501843A1 (en)	2015-12-07
AR094978A1 (es)	2015-09-09
US9512132B2 (en)	2016-12-06
RS56148B1 (sr)	2017-11-30
PE20151539A1 (es)	2015-10-28
WO2014135507A1 (en)	2014-09-12
UA118666C2 (uk)	2019-02-25
US9694012B2 (en)	2017-07-04
EA027935B1 (ru)	2017-09-29
CA2897513A1 (en)	2014-09-12
ZA201505073B (en)	2016-07-27
PL2964646T3 (pl)	2017-09-29
CN105143220A (zh)	2015-12-09
JP6514119B2 (ja)	2019-05-15
KR102217297B1 (ko)	2021-02-22

Publication	Publication Date	Title
ZA201505397B (en)	2016-12-21	Novel pyrazole derivative
IL240863B (en)	2019-02-28	Amatoxin derivatives
SG11201506100XA (en)	2015-09-29	Pyridazinone-amides derivatives
IL240327B (en)	2019-01-31	New pyrazole derivatives
IL240496A0 (en)	2015-09-24	New derivatives of pyridine
ZA201601333B (en)	2019-12-18	Oxoquinazolinyl-butanamide derivatives
IL241363A0 (en)	2015-11-30	History of pyridine-4-yl
IL241293B (en)	2019-06-30	New triazole derivatives
SG11201605189YA (en)	2016-07-28	Imidazopyrazinone derivatives
IL241859B (en)	2019-05-30	Novel triazole derivatives
ZA201507146B (en)	2016-10-26	Pyrazole derivative
GB201313317D0 (en)	2013-09-11	Insugrip